Literature DB >> 29906243

The chemerin knockout rat reveals chemerin dependence in female, but not male, experimental hypertension.

Stephanie W Watts1, Emma S Darios1, Adam E Mullick2, Hannah Garver1, Thomas L Saunders3,4, Elizabeth D Hughes3, Wanda E Filipiak3, Michael G Zeidler3, Nichole McMullen5, Christopher J Sinal5, Ramya K Kumar1, David J Ferland1, Gregory D Fink1.   

Abstract

Measures of the adipokine chemerin are elevated in multiple cardiovascular diseases, including hypertension, but little mechanistic work has been done to implicate chemerin as being causative in such diseases. The chemerin knockout (KO) rat was created to test the hypothesis that removal of chemerin would reduce pressure in the normal and hypertensive state. Western analyses confirmed loss of chemerin in the plasma and tissues of the KO vs. wild-type (WT) rats. Chemerin concentration in plasma and tissues was lower in WT females than in WT males, as determined by Western analysis. Conscious male and female KO rats had modest differences in baseline measures vs. the WT that included systolic, diastolic, mean arterial and pulse pressures, and heart rate, all measured telemetrically. The mineralocorticoid deoxycorticosterone acetate (DOCA) and salt water, combined with uninephrectomy as a hypertensive stimulus, elevated mean and systolic blood pressures of the male KO higher than the male WT. By contrast, all pressures in the female KO were lower than their WT throughout DOCA-salt treatment. These results revealed an unexpected sex difference in chemerin expression and the ability of chemerin to modify blood pressure in response to a hypertensive challenge.-Watts, S. W., Darios, E. S., Mullick, A. E., Garver, H., Saunders, T. L., Hughes, E. D., Filipiak, W. E., Zeidler, M. G., McMullen, N., Sinal, C. J., Kumar, R. K., Ferland, D. J., Fink, G. D. The chemerin knockout rat reveals chemerin dependence in female, but not male, experimental hypertension.

Entities:  

Keywords:  adipokines; blood pressure; vascular contraction

Year:  2018        PMID: 29906243      PMCID: PMC6219827          DOI: 10.1096/fj.201800479

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  95 in total

1.  Circulating concentrations of the novel adipokine chemerin are associated with cardiovascular disease risk in rheumatoid arthritis.

Authors:  Patrick H Dessein; Linda Tsang; Angela J Woodiwiss; Gavin R Norton; Ahmed Solomon
Journal:  J Rheumatol       Date:  2014-07-15       Impact factor: 4.666

Review 2.  Chemerin: at the crossroads of inflammation and obesity.

Authors:  Matthew C Ernst; Christopher J Sinal
Journal:  Trends Endocrinol Metab       Date:  2010-11       Impact factor: 12.015

3.  Peptidase inhibitor 16 is a membrane-tethered regulator of chemerin processing in the myocardium.

Authors:  Michael Regn; Bernhard Laggerbauer; Claudia Jentzsch; Deepak Ramanujam; Andrea Ahles; Sonja Sichler; Julia Calzada-Wack; Rory R Koenen; Attila Braun; Bernhard Nieswandt; Stefan Engelhardt
Journal:  J Mol Cell Cardiol       Date:  2016-08-15       Impact factor: 5.000

Review 4.  Adipokines in psoriasis: An important link between skin inflammation and metabolic alterations.

Authors:  Kerstin Wolk; Robert Sabat
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

5.  A novel adipocytokine, chemerin exerts anti-inflammatory roles in human vascular endothelial cells.

Authors:  Hideyuki Yamawaki; Satoshi Kameshima; Tatsuya Usui; Muneyoshi Okada; Yukio Hara
Journal:  Biochem Biophys Res Commun       Date:  2012-05-24       Impact factor: 3.575

6.  Chemerin level in pregnancies complicated by preeclampsia and its relation with disease severity and neonatal outcomes.

Authors:  Orkun Cetin; Zehra Kurdoglu; Mertihan Kurdoglu; H Guler Sahin
Journal:  J Obstet Gynaecol       Date:  2016-11-21       Impact factor: 1.246

7.  Pro- and Anti-Inflammatory Role of ChemR23 Signaling in Pollutant-Induced Inflammatory Lung Responses.

Authors:  Sharen Provoost; Katrien C De Grove; Graeme L Fraser; Vincent J Lannoy; Kurt G Tournoy; Guy G Brusselle; Tania Maes; Guy F Joos
Journal:  J Immunol       Date:  2016-01-15       Impact factor: 5.422

8.  Evidence from studies in rodents and in isolated adipocytes that agonists of the chemerin receptor CMKLR1 may be beneficial in the treatment of type 2 diabetes.

Authors:  Edward T Wargent; Mohamed S Zaibi; Jacqueline F O'Dowd; Michael A Cawthorne; Steven J Wang; Jonathan R S Arch; Claire J Stocker
Journal:  PeerJ       Date:  2015-02-05       Impact factor: 2.984

9.  Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids.

Authors:  Valérie Wittamer; Jean-Denis Franssen; Marisa Vulcano; Jean-François Mirjolet; Emmanuel Le Poul; Isabelle Migeotte; Stéphane Brézillon; Richard Tyldesley; Cédric Blanpain; Michel Detheux; Alberto Mantovani; Silvano Sozzani; Gilbert Vassart; Marc Parmentier; David Communi
Journal:  J Exp Med       Date:  2003-10-06       Impact factor: 14.307

10.  Synthetic chemerin-derived peptides suppress inflammation through ChemR23.

Authors:  Jenna L Cash; Rosie Hart; Andreas Russ; John P C Dixon; William H Colledge; Joanne Doran; Alan G Hendrick; Mark B L Carlton; David R Greaves
Journal:  J Exp Med       Date:  2008-04-07       Impact factor: 14.307

View more
  11 in total

Review 1.  Rat models of human diseases and related phenotypes: a systematic inventory of the causative genes.

Authors:  Claude Szpirer
Journal:  J Biomed Sci       Date:  2020-08-02       Impact factor: 8.410

2.  14-3-3ζ-TRAF5 axis governs interleukin-17A signaling.

Authors:  Jenna McGowan; Cara Peter; Joshua Kim; Sonam Popli; Brent Veerman; Jessica Saul-McBeth; Heather Conti; Shondra M Pruett-Miller; Saurabh Chattopadhyay; Ritu Chakravarti
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-23       Impact factor: 11.205

3.  Greater T Regulatory Cells in Females Attenuate DOCA-Salt-Induced Increases in Blood Pressure Versus Males.

Authors:  Kasey M Belanger; G Ryan Crislip; Ellen E Gillis; Mahmoud Abdelbary; Jacqueline B Musall; Riyaz Mohamed; Babak Baban; Ahmed Elmarakby; Michael W Brands; Jennifer C Sullivan
Journal:  Hypertension       Date:  2020-04-27       Impact factor: 10.190

Review 4.  Chemerin Isoforms and Activity in Obesity.

Authors:  Christa Buechler; Susanne Feder; Elisabeth M Haberl; Charalampos Aslanidis
Journal:  Int J Mol Sci       Date:  2019-03-05       Impact factor: 5.923

Review 5.  G-Protein Coupled Receptor Targeting on Myeloid Cells in Atherosclerosis.

Authors:  Emiel P C van der Vorst; Linsey J F Peters; Madeleine Müller; Selin Gencer; Yi Yan; Christian Weber; Yvonne Döring
Journal:  Front Pharmacol       Date:  2019-05-22       Impact factor: 5.810

6.  Endogenous Chemerin from PVAT Amplifies Electrical Field-Stimulated Arterial Contraction: Use of the Chemerin Knockout Rat.

Authors:  Emma D Flood; Stephanie W Watts
Journal:  Int J Mol Sci       Date:  2020-09-02       Impact factor: 5.923

7.  Chemerin as a Driver of Hypertension: A Consideration.

Authors:  David J Ferland; Adam E Mullick; Stephanie W Watts
Journal:  Am J Hypertens       Date:  2020-11-03       Impact factor: 2.689

Review 8.  Role of Chemerin/ChemR23 axis as an emerging therapeutic perspective on obesity-related vascular dysfunction.

Authors:  Yingying Xie; Ling Liu
Journal:  J Transl Med       Date:  2022-03-22       Impact factor: 5.531

9.  Chemerin contributes to in vivo adipogenesis in a location-specific manner.

Authors:  David J Ferland; Hannah Garver; G Andres Contreras; Gregory D Fink; Stephanie W Watts
Journal:  PLoS One       Date:  2020-02-24       Impact factor: 3.240

10.  Expression of Retinoid Acid Receptor-Responsive Genes in Rodent Models of Placental Pathology.

Authors:  Alexander Mocker; Marius Schmidt; Hanna Huebner; Rainer Wachtveitl; Nada Cordasic; Carlos Menendez-Castro; Andrea Hartner; Fabian B Fahlbusch
Journal:  Int J Mol Sci       Date:  2019-12-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.